Tucotuzumab Celmoleukin Overview

Introduction of Tucotuzumab celmoleukin

Tucotuzumab celmoleukin is a fusion protein consisting in a humanized monoclonal antibody and an interleukin-2 factor. The humanized monoclonal antibody of this drug is tucotuzumab, which can recognize and bind to the epithelial cell adhesion molecule (EpCAM or KS), a cell surface epithelial protein expressed in a variety of cancer cells. The interleukin-2 drug partially coupled with the antibody is celmoleukin, which can stimulate the anti-tumor immune response of cytotoxic T cells. The drug was developed by EMD Pharmaceuticals and has been used in the treatment of ovarian cancer and small cell lung cancer.

Mechanism of Action of Tucotuzumab celmoleukin

Tucotuzumab celmoleukin is designed as an antineoplastics that is comprised of monoclonal antibody and active interleukin-2 (IL2) molecule. The monoclonal antibody is responsible for recognizing and binding to EpCAM. EpCAM is a kind of cell adhesion molecule, which is involved in the interaction between cells and extracellular matrix. This is a protein that has been identified to be associated with tumor expression and is encoded by the TACSTD1 gene. EpCAM protein contains 314 amino acids and contains three domains in three-dimensional structure, namely, extracellular domain (EpEX), transmembrane domain and intracellular domain (EpICD). EpCAM can promote the proliferation, migration, invasion and tumor of tumor cells after cleavage and activation. The overexpression of EpCAM may lead to the activation of Wnt-β-catenin signaling pathway, which activates the expression of proto-oncogenes e-myc and cyclinA/E through wnt cascade reaction, and induces cell proliferation. Wnt signaling pathway exists in multicellular organisms, which controls cell performance and regulates complex intercellular information transmission through multiple downstream signaling pathways. It involves cell proliferation, stem cell maintenance, cell fate determination, cell migration and tissue polarity and other information regulation. Because EpCAM is a widely expressed tumor surface antigen, it may be used as a target for immunotherapy of most tumors. Tucotuzumab celmoleukin is a recombinant fusion protein drug targeting EpCAM. After administration, the protein part of the drug, Tucotuzumab, specifically recognizes and binds to EpCAM on the surface of tumor cells. Then, the coupled interleukin-2 drug is expressed in the combined tumor cell tissue, killing tumor cells by activating cytotoxic T cells.

Fig 1. Mechanism of Action of Tucotuzumab celmoleukin

What We Provide

Therapeutic Antibody

Tucotuzumab Celmoleukin

We provide high-quality Tucotuzumab Celmoleukin for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

For research use only. Not intended for any clinical use.